Ovarian Cancer Trial, Recruiting NCT06041204 Sponsor: Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06041204
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 20 and 40 years
  • People with a body mass index (a measure of body weight relative to height) between 18 and 35
  • People diagnosed with polycystic ovary syndrome (PCOS) based on specific recognised criteria, which includes irregular or absent periods, signs of higher-than-normal male hormones, and polycystic ovaries seen on an ultrasound
  • People with a mildly underactive thyroid, meaning a specific thyroid hormone level (TSH) is slightly elevated (between 5–10 mIU/L) while another thyroid hormone (free T4) remains in the normal range
  • People who have been trying to conceive without success for at least one year
  • People confirmed to have both ovaries and a uterus intact, verified by physical examination and imaging
  • People whose male partner has a normal semen analysis result
  • People where no blockage or scarring of the fallopian tubes or surrounding pelvic area is contributing to infertility
  • People using effective contraception if they are not currently trying to conceive
  • People who are willing and able to give informed consent to participate

Who may not be able to join:

  • People who have a previously known thyroid condition or are currently taking thyroid medication
  • People with thyroid test results that are abnormal in ways other than the mild elevation described above
  • People with elevated levels of the hormone prolactin (hyperprolactinemia)
  • People whose infertility is related to other specific causes, such as moderate to severe male fertility problems, both fallopian tubes being blocked, stage III or IV endometriosis, or ovarian failure or low ovarian reserve
  • People who have previously been diagnosed with congenital adrenal hyperplasia (a hormonal condition present from birth)
  • People with poorly controlled diabetes, indicated by a specific blood sugar marker (HbA1c) above 8%
  • People with a history of blood clots in the veins (such as deep vein thrombosis) or related conditions
  • People for whom either of the two study medications — letrozole or levothyroxine — would not be medically appropriate (confirm with trial site)
  • People who have used letrozole or levothyroxine within the past 6 months
  • People who are currently pregnant or where pregnancy is suspected
  • People who are currently breastfeeding
  • People who would be unable to follow the treatment plan and attend required follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Muhamed Alhagrasy, M.D., Al-Azhar University

Phone: 01017313413

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
Registry
ClinicalTrials.gov
Start date
6 May 2021
Est. completion
30 May 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Pregnancy rate; Live birth rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov